论文部分内容阅读
目的研究东菱克栓酶治疗急性脑梗死的疗效和安全性。方法将临床确诊为脑梗死的患者并且发病在72h以内的120例患者随机分为两组,即治疗组和对照组。治疗组患者入院后给予急诊化验血凝分析和血常规,在纤维蛋白原不低于2g/L和血小板正常的情况下,首次给予东菱克栓酶10Bu入液静滴。第3日和第5日均化验血凝分析,在纤维蛋白原不低于1g/L的情况下,给予东菱克栓酶5Bu入液静滴,并常规给予阿司匹林、银杏达莫、胞二磷胆碱治疗。对照组只给予阿司匹林、银杏达莫、胞二磷胆碱常规治疗。结果东菱克栓酶治疗组有效率91.7%,对照组有效率78.3%(P<0.01),结论东菱克栓酶治疗急性脑梗死疗效显著,安全可靠。
Objective To study the curative effect and safety of Batroxobin in the treatment of acute cerebral infarction. Methods A total of 120 patients with clinically diagnosed as cerebral infarction and with onset within 72 h were randomly divided into two groups: treatment group and control group. Patients in the treatment group were given emergency laboratory tests of hemagglutination and blood tests after admission. In the case of no less than 2g / L of fibrinogen and normal platelets, the patients were given glibenclamide 10Bu intravenously. On the 3rd and 5th day, hemagglutination analysis was performed. When fibrinogen was not less than 1g / L, glibenclamide 5Bu was given intravenously and routinely given aspirin, ginkgo biloba, Choline treatment. The control group was given aspirin, ginkgo biloba, citicoline routine treatment. Results Batroxobin treatment group was 91.7% effective rate, the control group was 78.3% (P <0.01), Conclusion Curative effect of rhubarb thrombus treatment of acute cerebral infarction significant, safe and reliable.